CD40对晚期上皮性卵巢癌新辅助化疗敏感性的预测价值

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (47 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo determine the influence of neoadjuvant chemotherapy(NACT)on the expression of CD40 in ovarian cancer,and further infer whether the CD40 molecule can be used as a biological marker to predict the chemosensitivity of ovarian cancer by examining the expression of CD40 in ovarian cancer tissue.MethodsEighty patients with advanced epithelial ovarian cancer treated in our hospital from December 2015 to December 2017 were selected and they were classified into group A　(n=30)given NACT and group B　(n=50)without NACT according to whether they performed neoadjuvant chemotherapy before surgery or not.The corresponding paraffin sections of ovarian cancer tissues were 30 and 50 respectively.Immunohistochemical method was used to detect the expression of CD40 in two groups of ovarian cancer tissue.ResultsThe total effective rate of chemotherapy in group A　(80.00%)was significantly higher than that of group B　(58.00%),and the difference was statistically significant(P＜0.05).The positive expression rate of CD40 in group A(56.67%)was lower than that of group B(80.00%),and the difference was statistically significant(P＜0.05).The positive expression rate of CD40 in chemo effective patients　(45.83%)was significantly lower than that in chemo ineffective patients(100.00%)of group A,and the difference was statistically significant(P＜0.05).The expression of CD40 in advanced ovarian cancer was positively correlated with Ki-67　(r=0.539,P=0.000).ConclusionThe expression of CD40 was significantly different between NACT and NACT of advanced ovarian cancer.CD40 can be used as a biomarker for predicting the sensitivity of NACT,and it helps to guide the application of NACT in advanced ovarian cancer.

Key words： Ovarian cancer Neoadjuvant chemotherapy CD40 Ki-67 Immunohistochemistry

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Xiao-qing
	LIU Yu-ling

Cite this article:

CHEN Xiao-qing,LIU Yu-ling. Predictive value of CD40 on the sensitivity of neoadjuvant chemotherapy in advanced epithelial ovarian cancer[J]. 中国当代医药, 2018, 25(18): 17-20.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I18/17

[2]	常凌雅，马冬，李鸥，等.Krüppel样因子 5和肿瘤坏死因子受体超家族成员11a在宫颈癌组织及细胞中的表达及其作用[J].中国医学科学院学报，2017，39（2）：196-205.
[3]	邹美娜，毕国荣.可溶性CD40配体与心脑血管疾病关系的研究进展[J].实用心脑肺血管病杂志，2016，24（3）：5-8.
[1]	丁贤彬，吕晓燕，毛德强.2006-2014年重庆肿瘤登记地区卵巢癌发病率及趋势变化[J].中华预防医学杂志，2016，50（3）：274-276.
[4]	Kessous R，Laskov I，Abitbol J，et al.Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer[J].Gynecol Oncol，2017，144（3）：474-479.
[5]	徐正美.新辅助化疗联合中间性肿瘤细胞减灭术治疗晚期上皮性卵巢癌及卵巢癌预后影响因素的临床分析[D].广州：南方医科大学，2013.
[6]	边策，綦小蓉，姚奎，等.新辅助化疗对晚期卵巢癌治疗应用价值的评估及多因素分析[J].实用妇产科杂志，2016，32（4）：266-271.
[7]	冯仙明，陈焕伟，王博，等.初始化疗或手术对Ⅲ期卵巢癌的临床疗效分析[J].肿瘤药学，2016，6（5）：375-378.
[8]	Hu CY，Zhang X，Meyer CG，et al.Polymorphism of X-linked CD40 ligand gene associated with pulmonary tuberculosis in the Han Chinese population[J].Genes Immun，2015，16（6）：399-410.
[9]	侯学涛，田洪帅，李敏，等.CD40和Id4在子宫内膜癌的表达及意义[J].社区学杂志，2017，15（13）：20-23.
[10]	赵烨，刘玺，王若愚，等.CD40/CD40L系统对B淋巴细胞的作用研究进展[J].细胞与分子免疫学杂志，2015，31（5）：716-719.
[11]	封忠昕，陈琦，王永伦，等.可溶性CD40配体对白血病HL-60细胞Caspase-3及Caspase-8表达的影响 [J].中华肿瘤防治杂志，2016，23（19）：1287-1290.
[12]	胡荣，朱珂，李佳.B细胞非霍奇金淋巴瘤中CD40和NF-κB 表达及意义[J].临床与实验病理学杂志，2013，29（2）：131-133.
[13]	田文妍，陈卫昌.CD40、PI3K、p-Akt、VEGF 在人胃腺癌中的表达和意义[J].胃肠病学，2011，16（7）：404-408.
[14]	侯学涛，田洪帅，李敏，等，CD40和Id4在子宫内膜癌的表达及意义[J].社区学杂志，2017，15（13）：20-23.
[15]	黄沁，瞿秋霞，谢芳，等.宫颈癌组织中CD40分子表达的临床意义及其与肿瘤血管生长的相关性[J].苏州大学学报（医学版），2012，32（4）：532-539.
[16]	黄建安，顾冬梅，庄羽美，等.CD40分子在肺癌中的表达及其临床意义[J].江苏医药杂志，2003，29（9）：645-647.
[17]	Yahara K，Ohguri T，Imada H，et al.Epithelial ovarian cancer：definitive radiotherapy for limited recurrence after complete remission had been achieved with aggressive frontline therapy[J].J Radiat Res，2013，54 （2）：322-329.
[18]	郭贵龙，姚榛祥.p27及ki67对鉴别良恶性甲状腺滤泡状肿瘤的价值[J].中国普通外科杂志，2002，11（5）：289-292.
[19]	Qin QI，Gao F.Effect of neoadjuvant chemotherapy on expressions of estrogen receptor，progesterone receptor，human epidermal growth factor receptor 2，and Ki-67 in breast cancer[J].Chin Med J （Engl），2014，127（18）：3272-3277.
[20]	Wu A，Jia Y，Dong B，et al.Apoptosis and KI 67 index correlate with preoperative chemotherapy efficacy and better predictthesurvivalofgastriccancerpatientswithcombined therapy[J].Cancer Chemother Pharmacol，2014，73（5）：885-893.